Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.

@article{Bonnefoi2007ValidationOG,
  title={Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.},
  author={Herv{\'e} R. Bonnefoi and Anil Potti and Mauro Delorenzi and Louis Mauriac and Mario Campone and Mich{\`e}le Tubiana-Hulin and Thierry Petit and P Rouanet and Jacek Jassem and Emmanuel Blot and V{\'e}ronique Becette and Pierre J Farmer and Sylvie Andre and Chaitanya R. Acharya and Sayan Mukherjee and David A. Cameron and Jonas Bergh and J. R. Nevins and Richard D. Iggo},
  journal={The Lancet. Oncology},
  year={2007},
  volume={8 12},
  pages={1071-1078}
}
BACKGROUND We have previously described gene-expression signatures that predict growth inhibitory and cytotoxic effects of common chemotherapeutic drugs in vitro. The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial. METHODS This trial compares a non-taxane regimen (fluorouracil, epirubicin, and cyclophosphamide [FEC] for six… CONTINUE READING